Teplizumab
From Wikipedia, the free encyclopedia
|
Teplizumab?
|
|
| Therapeutic monoclonal antibody | |
| Source | Human |
| Target | CD3 |
| Identifiers | |
| CAS number | ? |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Teplizumab is a monoclonal antibody which it is used as an immunosuppressive drug. It is a humanized Fc-engineered monoclonal antibody also known as MGA031 and hOKT3γ1(Ala-Ala)[1][2].
[edit] References
- ^ Woodle, E.S., Bluestone, J., Zivin, R., Jolliffe, L., Auger, J., Xu, D., and J. Thistlethwaite. "Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience." (1998) Transplant Proc. 30:1369-1370
- ^ Brown, W.M. "Anti-CD3 antibody MacroGenics Inc." (2006) Curr Opin Investig Drugs, 74:381-8.
[edit] External links
- [1] MacroGenics, Inc.
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||||||||
Zues
